Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia

Next Previous
Trial Profile

A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brincidofovir (Primary) ; Cidofovir; Ganciclovir; Ribavirin
  • Indications Adenovirus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chimerix

Most Recent Events

  • 09 May 2019 Status changed from recruiting to discontinued, according to a Chimerix media release.
  • 14 Aug 2018 Status changed from not yet recruiting to recruiting.
  • 16 Jul 2018 Planned primary completion date changed from 30 May 2019 to 30 Sep 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top